Other

Zealand Pharma A/s

Poseidon Pharmaceuticals A/s

Camilla Ærteberg Bæk

Ditte Riber

Jakob Lind Tolborg

Eddi Meier

Jens Rosengren Daugaard

Marie Skovgaard

Gita Kampen

Søren Peter Olesen

Lars Siim Madsen

Annette Lauridsen

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Acylated glucagon analogues

The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Certain 1,5-disubstituted benzimidazol-2-one compounds useful as therapeutic agents. The compounds may be of the Formula I wherein: R' represents hydrogen or alkyl; R&#x2033; represents halogen or trihalogenmethyl; and Hlg represents halogen; provided, however, that if Hlg is F, then R&#x2033; is not Cl. Also, use of the 1,5-disubstituted benzimidazol-2-one compounds, or pharmaceutically-acceptable addition salts thereof, in applications that benefit from increasing the blood-brain barrier permeability.

Benzimidazol-2-one derivatives and their use

Growing community of inventors

Allerød, Denmark

Camilla Ærteberg Bæk